Percentage of Teratoma in Orchiectomy and Risk of Retroperitoneal Teratoma at the Time of Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors
- 1 December 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 206 (6), 1430-1437
- https://doi.org/10.1097/ju.0000000000001960
Abstract
Introduction: Presence of teratoma in the orchiectomy and residual retroperitoneal mass size are known predictors of finding teratoma during post-chemotherapy retroperitoneal lymph node dissections (PC-RPLND). We sought to determine if the percentage of teratoma in the orchiectomy specimen could better stratify the risk of teratoma in the retroperitoneum. Materials and Methods: The Indiana University testis cancer database was reviewed to identify patients who underwent PC-RPLND for non-seminomatous germ cell tumors from 2010-2018. A logistic regression model was fit to predict the presence of retroperitoneal teratoma using teratoma and yolk sac tumor (YST) in the orchiectomy, residual mass size, and log transformed values of pre-chemotherapy AFP and bHCG. The study cohort was split into 60% training and 40% validation sets using 200 bootstraps. A predictive nomogram was developed for predicting teratoma in the retroperitoneum. Results: A total of 422 men were included. Presence of teratoma in the orchiectomy (OR 1.02, p <0.001), residual mass size (OR 1.16, p <0.001) and log transformed pre-chemotherapy AFP (OR 1.12, p=0.002) were predictive factors for having teratoma in the retroperitoneum. The C-statistic using this model demonstrated a predictive ability of 0.77. Training set C-statistic was 0.78 compared to 0.75 for the validation set. A nomogram was developed to aid in clinical utility. Conclusion: The model better predicts patients at higher risk of teratoma in the retroperitoneum following chemotherapy which can aid in a more informed referral for surgical resection.Keywords
This publication has 12 references indexed in Scilit:
- Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell TumorJournal of Urology, 2018
- A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in NonseminomaEuropean Urology Focus, 2018
- Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumorsAnnals of Oncology, 2017
- Testicular cancer: The usage of central review for pathology diagnosis of orchiectomy specimensUrologic Oncology, 2017
- Complications of open primary and post-chemotherapy retroperitoneal lymph node dissection for testicular cancerUrologic Oncology, 2010
- Testicular Cancer Survivorship: Research Strategies and RecommendationsJNCI Journal of the National Cancer Institute, 2010
- Predicting Retroperitoneal Histology in Postchemotherapy Testicular Germ Cell Cancer: A Model Update and Multicentre Validation with More Than 1000 PatientsEuropean Urology, 2007
- Predicting Teratoma in the Retroperitoneum in Men Undergoing Post-Chemotherapy Retroperitoneal Lymph Node DissectionJournal of Urology, 2006
- HISTOLOGY IN MIXED GERM CELL TUMORS. IS THERE A FAVORITE PAIRING?Journal of Urology, 2004
- Teratoma in the Orchiectomy Specimen and Volume of Metastasis are Predictors of Retroperitoneal Teratoma in Post-Chemotherapy Nonseminomatous Testis CancerJournal of Urology, 2002